financetom
Business
financetom
/
Business
/
NV5 Deepens Data Center Push With Herman Cx Acquisition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NV5 Deepens Data Center Push With Herman Cx Acquisition
Mar 13, 2025 4:54 AM

NV5 Global ( NVEE ) has completed its acquisition of Herman Cx, a U.S.-based provider of commissioning and conformity assessment services for hyperscale data centers. The cash-and-stock deal is expected to be immediately accretive to NV5’s earnings. Financial terms were not disclosed.

Founded in 2016, Herman Cx supports critical infrastructure for leading U.S. technology companies, financial institutions, and co-location data centers. The firm offers design reviews and functional testing to ensure data center systems meet cooling, power, and safety requirements. It has commissioned infrastructure up to 175 MW and provides end-to-end critical testing, from individual components to full system integration.

NV5 CEO Ben Heraud said the acquisition strengthens the company’s hyperscale data center commissioning capabilities and supports its growth in the domestic market. He added that mission-critical commissioning also opens cross-selling opportunities across NV5’s MEP design, fire protection, and power delivery services while generating recurring revenue beyond the initial build phases.

“Data centers continue to be a strategic growth driver for NV5, generating over 20% organic growth,” said Andrew Chang, chief operating officer of buildings and technology. “We’re excited about the cross-selling potential this acquisition brings.”

The announcement follows NV5’s recent award of $18 million in data center design and commissioning contracts across the U.S. and Asia, further cementing its role in enabling efficient, resilient, and sustainable infrastructure for cloud and AI operations.

Price Action: NVEE shares closed lower by 2.03% to $17.41 o Wednesday.

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cameco Prices $366.8 Million Debenture Offering in Private Placement
Cameco Prices $366.8 Million Debenture Offering in Private Placement
May 21, 2024
05:41 PM EDT, 05/21/2024 (MT Newswires) -- Cameco ( CCJ ) said Tuesday it priced a private placement offering of CA$500 million ($366.8 million) of 4.94% senior unsecured debentures due 2031. The company said it expects the offering to close Friday. Cameco ( CCJ ) intends to use the net proceeds to retire all of its outstanding 4.19% senior unsecured...
BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours
BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours
May 21, 2024
05:49 PM EDT, 05/21/2024 (MT Newswires) -- BioCardia ( BCDA ) said late Tuesday it plans to implement a 1-for-15 reverse split of its common shares to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company expects its shares to start trading on a split-adjusted basis May 30. BioCardia ( BCDA ) shares...
Luna Innovations Gets Non-Compliance Notice From Nasdaq
Luna Innovations Gets Non-Compliance Notice From Nasdaq
May 21, 2024
05:41 PM EDT, 05/21/2024 (MT Newswires) -- Luna Innovations ( LUNA ) said Tuesday that it received a non-compliance notice from the Nasdaq Stock Market for failing to timely file its quarterly report on Form 10-Q for the quarter ended March 31 and annual report on Form 10-K for the year ended Dec. 31, 2023. Luna said it has until...
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship
May 21, 2024
05:51 PM EDT, 05/21/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said Tuesday it has aligned with Johnson & Johnson's ( JNJ ) Janssen Pharmaceutica at their Joint Strategy Committee to transfer the global sponsorship of the phase 3 head and neck cancer trial of NBTXR3 in preparation for potential regulatory submission in the event of positive trial results. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved